{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,31]],"date-time":"2026-07-31T22:13:45Z","timestamp":1785536025142,"version":"3.56.0"},"reference-count":39,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2023,3,1]],"date-time":"2023-03-01T00:00:00Z","timestamp":1677628800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2023,3,1]],"date-time":"2023-03-01T00:00:00Z","timestamp":1677628800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2023,2,13]],"date-time":"2023-02-13T00:00:00Z","timestamp":1676246400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Pharmacological Research"],"published-print":{"date-parts":[[2023,3]]},"DOI":"10.1016\/j.phrs.2023.106701","type":"journal-article","created":{"date-parts":[[2023,2,14]],"date-time":"2023-02-14T21:37:48Z","timestamp":1676410668000},"page":"106701","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":49,"special_numbering":"C","title":["Oncolytic adenovirus-mediated expression of CCL5 and IL12 facilitates CA9-targeting CAR-T therapy against renal cell carcinoma"],"prefix":"10.1016","volume":"189","author":[{"given":"Lin","family":"Fang","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Weiping","family":"Tian","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chen","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xueyan","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wanjing","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Qi","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yuxin","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Junnian","family":"Zheng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"3","key":"10.1016\/j.phrs.2023.106701_bib1","doi-asserted-by":"crossref","first-page":"228","DOI":"10.1097\/MOU.0000000000000864","article-title":"Renal cell carcinoma pathology in 2021: 'new need for renal cancer immune profiling'","volume":"31","author":"Sobottka","year":"2021","journal-title":"Curr. Opin. Urol."},{"issue":"15","key":"10.1016\/j.phrs.2023.106701_bib2","doi-asserted-by":"crossref","DOI":"10.3390\/ijms20153672","article-title":"Glutathione metabolism in renal cell carcinoma progression and implications for therapies","volume":"20","author":"Xiao","year":"2019","journal-title":"Int J. Mol. Sci."},{"key":"10.1016\/j.phrs.2023.106701_bib3","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1016\/j.ctrv.2018.02.009","article-title":"Renal cell carcinoma in one year: Going inside the news of 2017 - a report of the main advances in RCC cancer research","volume":"67","author":"Mosillo","year":"2018","journal-title":"Cancer Treat. Rev."},{"issue":"1","key":"10.1016\/j.phrs.2023.106701_bib4","doi-asserted-by":"crossref","first-page":"255","DOI":"10.1186\/s13046-019-1259-z","article-title":"Combination of CTLA-4 and PD-1 blockers for treatment of cancer","volume":"38","author":"Rotte","year":"2019","journal-title":"J. Exp. Clin. Cancer Res.: CR"},{"issue":"1","key":"10.1016\/j.phrs.2023.106701_bib5","doi-asserted-by":"crossref","first-page":"100","DOI":"10.1016\/j.eururo.2018.10.010","article-title":"Systemic treatment of metastatic clear cell renal cell carcinoma in 2018: Current paradigms, use of immunotherapy, and future directions","volume":"75","author":"Lalani","year":"2019","journal-title":"Eur. Urol."},{"key":"10.1016\/j.phrs.2023.106701_bib6","doi-asserted-by":"crossref","first-page":"246","DOI":"10.1016\/j.jconrel.2019.12.047","article-title":"Current challenges and emerging opportunities of CAR-T cell therapies","volume":"319","author":"Abreu","year":"2020","journal-title":"J. Control. Release: Off. J. Control. Release Soc."},{"issue":"S1","key":"10.1016\/j.phrs.2023.106701_bib7","doi-asserted-by":"crossref","first-page":"S3","DOI":"10.1002\/ajh.25418","article-title":"An introduction to chimeric antigen receptor (CAR) T-cell immunotherapy for human cancer","volume":"94","author":"Feins","year":"2019","journal-title":"Am. J. Hematol."},{"key":"10.1016\/j.phrs.2023.106701_bib8","doi-asserted-by":"crossref","first-page":"22","DOI":"10.1186\/s40364-017-0102-y","article-title":"Engineering CAR-T cells","volume":"5","author":"Zhang","year":"2017","journal-title":"Biomark. Res."},{"issue":"7","key":"10.1016\/j.phrs.2023.106701_bib9","doi-asserted-by":"crossref","first-page":"1721","DOI":"10.1016\/j.apsb.2020.12.015","article-title":"Cancer stem cell-targeted chimeric antigen receptor (CAR)-T cell therapy: challenges and prospects","volume":"11","author":"Masoumi","year":"2021","journal-title":"Acta Pharm. Sin. B."},{"issue":"9","key":"10.1016\/j.phrs.2023.106701_bib10","doi-asserted-by":"crossref","first-page":"1341","DOI":"10.1038\/s41591-019-0564-6","article-title":"Clinical lessons learned from the first leg of the CAR T cell journey","volume":"25","author":"Majzner","year":"2019","journal-title":"Nat. Med."},{"issue":"3","key":"10.1016\/j.phrs.2023.106701_bib11","doi-asserted-by":"crossref","DOI":"10.3390\/cancers14030571","article-title":"Strategies for improving the efficacy of CAR T cells in solid cancers","volume":"14","author":"Kyte","year":"2022","journal-title":"Cancers"},{"issue":"3","key":"10.1016\/j.phrs.2023.106701_bib12","doi-asserted-by":"crossref","first-page":"147","DOI":"10.1038\/s41571-019-0297-y","article-title":"Engineering strategies to overcome the current roadblocks in CAR T cell therapy","volume":"17","author":"Rafiq","year":"2020","journal-title":"Nat. Rev. Clin. Oncol."},{"issue":"4","key":"10.1016\/j.phrs.2023.106701_bib13","doi-asserted-by":"crossref","first-page":"1417","DOI":"10.1111\/cas.14835","article-title":"Anti-tumor efficacy of human anti-c-met CAR-T cells against papillary renal cell carcinoma in an orthotopic model","volume":"112","author":"Mori","year":"2021","journal-title":"Cancer Sci."},{"issue":"4","key":"10.1016\/j.phrs.2023.106701_bib14","doi-asserted-by":"crossref","first-page":"904","DOI":"10.1038\/mt.2013.17","article-title":"Treatment of metastatic renal cell carcinoma with CAIX CAR-engineered T cells: clinical evaluation and management of on-target toxicity","volume":"21","author":"Lamers","year":"2013","journal-title":"Mol. Ther.: J. Am. Soc. Gene Ther."},{"issue":"1","key":"10.1016\/j.phrs.2023.106701_bib15","doi-asserted-by":"crossref","DOI":"10.1016\/j.currproblcancer.2020.100639","article-title":"Oncolytic virotherapy: challenges and solutions","volume":"45","author":"Goradel","year":"2021","journal-title":"Curr. Probl. Cancer"},{"issue":"18","key":"10.1016\/j.phrs.2023.106701_bib16","doi-asserted-by":"crossref","first-page":"1673","DOI":"10.1056\/NEJMoa1106152","article-title":"Inducible apoptosis as a safety switch for adoptive cell therapy","volume":"365","author":"Di Stasi","year":"2011","journal-title":"N. Engl. J. Med."},{"issue":"8","key":"10.1016\/j.phrs.2023.106701_bib17","doi-asserted-by":"crossref","DOI":"10.3390\/pharmaceutics14081630","article-title":"Cancer immunotherapy and delivery system: an update","volume":"14","author":"Yang","year":"2022","journal-title":"Pharmaceutics"},{"key":"10.1016\/j.phrs.2023.106701_bib18","first-page":"47","article-title":"Cell carriers for oncolytic viruses: current challenges and future directions","volume":"2","author":"Roy","year":"2013","journal-title":"Oncol. Virother"},{"key":"10.1016\/j.phrs.2023.106701_bib19","doi-asserted-by":"crossref","DOI":"10.1016\/j.pharmthera.2020.107586","article-title":"Strategies for enhancing intratumoral spread of oncolytic adenoviruses","volume":"213","author":"Goradel","year":"2020","journal-title":"Pharmacol. Ther."},{"issue":"7","key":"10.1016\/j.phrs.2023.106701_bib20","doi-asserted-by":"crossref","first-page":"1275","DOI":"10.1038\/mt.2010.79","article-title":"Hyaluronidase expression by an oncolytic adenovirus enhances its intratumoral spread and suppresses tumor growth","volume":"18","author":"Guedan","year":"2010","journal-title":"Mol. Ther.: J. Am. Soc. Gene Ther."},{"key":"10.1016\/j.phrs.2023.106701_bib21","doi-asserted-by":"crossref","first-page":"155","DOI":"10.1016\/j.canlet.2017.03.009","article-title":"Oncolytic adenovirus expressing relaxin (YDC002) enhances therapeutic efficacy of gemcitabine against pancreatic cancer","volume":"396","author":"Jung","year":"2017","journal-title":"Cancer Lett."},{"issue":"10","key":"10.1016\/j.phrs.2023.106701_bib22","doi-asserted-by":"crossref","DOI":"10.1371\/journal.ppat.1003718","article-title":"Penton-dodecahedral particles trigger opening of intercellular junctions and facilitate viral spread during adenovirus serotype 3 infection of epithelial cells","volume":"9","author":"Lu","year":"2013","journal-title":"PLoS Pathog."},{"issue":"5","key":"10.1016\/j.phrs.2023.106701_bib23","doi-asserted-by":"crossref","first-page":"229","DOI":"10.5501\/wjv.v10.i5.229","article-title":"Oncolytic virus therapy in cancer: a current review","volume":"10","author":"Santos Apolonio","year":"2021","journal-title":"World J. Virol."},{"issue":"1","key":"10.1016\/j.phrs.2023.106701_bib24","doi-asserted-by":"crossref","first-page":"16","DOI":"10.1186\/s12957-021-02486-x","article-title":"Overview of the pre-clinical and clinical studies about the use of CAR-T cell therapy of cancer combined with oncolytic viruses","volume":"20","author":"Zarezadeh Mehrabadi","year":"2022","journal-title":"World J. Surg. Oncol."},{"issue":"2","key":"10.1016\/j.phrs.2023.106701_bib25","doi-asserted-by":"crossref","first-page":"505","DOI":"10.1016\/j.ymthe.2020.10.023","article-title":"Clinical CAR-T cell and oncolytic virotherapy for cancer treatment","volume":"29","author":"Watanabe","year":"2021","journal-title":"Mol. Ther."},{"key":"10.1016\/j.phrs.2023.106701_bib26","doi-asserted-by":"crossref","first-page":"398","DOI":"10.1016\/j.cyto.2018.05.019","article-title":"Emerging IL-12 family cytokines in the fight against fungal infections","volume":"111","author":"Thompson","year":"2018","journal-title":"Cytokine"},{"issue":"2","key":"10.1016\/j.phrs.2023.106701_bib27","doi-asserted-by":"crossref","DOI":"10.3390\/cancers12020287","article-title":"Chemokines and their receptors: multifaceted roles in cancer progression and potential value as cancer prognostic markers","volume":"12","author":"Do","year":"2020","journal-title":"Cancers"},{"issue":"6","key":"10.1016\/j.phrs.2023.106701_bib28","doi-asserted-by":"crossref","first-page":"885","DOI":"10.1016\/j.ccell.2019.05.004","article-title":"Cooperation between Constitutive and inducible chemokines enables T cell engraftment and immune attack in solid tumors","volume":"35","author":"Dangaj","year":"2019","journal-title":"Cancer Cell"},{"issue":"1","key":"10.1016\/j.phrs.2023.106701_bib29","doi-asserted-by":"crossref","first-page":"75","DOI":"10.1016\/j.eururo.2010.03.015","article-title":"Carbonic anhydrase IX in renal cell carcinoma: implications for prognosis, diagnosis, and therapy","volume":"58","author":"Stillebroer","year":"2010","journal-title":"Eur. Urol."},{"key":"10.1016\/j.phrs.2023.106701_bib30","doi-asserted-by":"crossref","first-page":"14","DOI":"10.1016\/j.omto.2021.11.018","article-title":"Oncolytic adenovirus-mediated expression of decorin facilitates CAIX-targeting CAR-T therapy against renal cell carcinoma","volume":"24","author":"Zhang","year":"2022","journal-title":"Mol. Ther. Oncolytics"},{"issue":"Suppl 2","key":"10.1016\/j.phrs.2023.106701_bib31","doi-asserted-by":"crossref","first-page":"810","DOI":"10.1038\/s41409-019-0604-3","article-title":"The role of allogeneic HSCT after CAR T cells for acute lymphoblastic leukemia","volume":"54","author":"Jacoby","year":"2019","journal-title":"Bone Marrow Transpl."},{"issue":"1","key":"10.1016\/j.phrs.2023.106701_bib32","doi-asserted-by":"crossref","first-page":"64","DOI":"10.1056\/NEJMra1706169","article-title":"Chimeric antigen receptor therapy","volume":"379","author":"June","year":"2018","journal-title":"N. Engl. J. Med."},{"issue":"5","key":"10.1016\/j.phrs.2023.106701_bib33","doi-asserted-by":"crossref","first-page":"439","DOI":"10.1056\/NEJMoa1709866","article-title":"Tisagenlecleucel in children and young adults with B-cell lymphoblastic leukemia","volume":"378","author":"Maude","year":"2018","journal-title":"N. Engl. J. Med."},{"issue":"26","key":"10.1016\/j.phrs.2023.106701_bib34","doi-asserted-by":"crossref","first-page":"2531","DOI":"10.1056\/NEJMoa1707447","article-title":"Axicabtagene ciloleucel CAR T-cell therapy in refractory large B-cell lymphoma","volume":"377","author":"Neelapu","year":"2017","journal-title":"N. Engl. J. Med"},{"key":"10.1016\/j.phrs.2023.106701_bib35","doi-asserted-by":"crossref","first-page":"2460","DOI":"10.3389\/fimmu.2018.02460","article-title":"CAR-T cells and oncolytic viruses: joining forces to overcome the solid tumor challenge","volume":"9","author":"Guedan","year":"2018","journal-title":"Front Immunol."},{"issue":"16","key":"10.1016\/j.phrs.2023.106701_bib36","doi-asserted-by":"crossref","first-page":"4262","DOI":"10.1158\/1078-0432.CCR-13-2627","article-title":"Multifactorial T-cell hypofunction that is reversible can limit the efficacy of chimeric antigen receptor-transduced human T cells in solid tumors","volume":"20","author":"Moon","year":"2014","journal-title":"Clin. Cancer Res.: Off. J. Am. Assoc. Cancer Res."},{"issue":"7","key":"10.1016\/j.phrs.2023.106701_bib37","doi-asserted-by":"crossref","first-page":"364","DOI":"10.1016\/j.it.2012.02.006","article-title":"The three main stumbling blocks for anticancer T cells","volume":"33","author":"Baitsch","year":"2012","journal-title":"Trends Immunol."},{"issue":"8","key":"10.1016\/j.phrs.2023.106701_bib38","doi-asserted-by":"crossref","first-page":"486","DOI":"10.1038\/nri3862","article-title":"Molecular and cellular insights into T cell exhaustion","volume":"15","author":"Wherry","year":"2015","journal-title":"Nat. Rev. Immunol."},{"issue":"2","key":"10.1016\/j.phrs.2023.106701_bib39","doi-asserted-by":"crossref","first-page":"162","DOI":"10.1002\/path.2803","article-title":"Jekyll and Hyde: the role of the microenvironment on the progression of cancer","volume":"223","author":"Allen","year":"2011","journal-title":"J. Pathol."}],"container-title":["Pharmacological Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1043661823000579?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1043661823000579?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2024,12,10]],"date-time":"2024-12-10T21:33:31Z","timestamp":1733866411000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1043661823000579"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,3]]},"references-count":39,"alternative-id":["S1043661823000579"],"URL":"https:\/\/doi.org\/10.1016\/j.phrs.2023.106701","relation":{},"ISSN":["1043-6618"],"issn-type":[{"value":"1043-6618","type":"print"}],"subject":[],"published":{"date-parts":[[2023,3]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Oncolytic adenovirus-mediated expression of CCL5 and IL12 facilitates CA9-targeting CAR-T therapy against renal cell carcinoma","name":"articletitle","label":"Article Title"},{"value":"Pharmacological Research","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.phrs.2023.106701","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2023 The Authors. Published by Elsevier Ltd.","name":"copyright","label":"Copyright"}],"article-number":"106701"}}